Promising Results of Initial Clinical Studies forNymox's New Urinary Test for Alzheimer'sDisease.
MONTREAL--(BUSINESS WIRE)--Oct. 21, 1997--NYMOX (ME NMX.) Nymox corporation is pleased to announce promising results in initial double blind clinical trials of its new urinary test for Alzheimer's disease. The study has included patients with Alzheimer's disease, normal controls and other
"The Nymox urinary Alzheimer's test is an extension of Nymox's NTP technology which has already been shown in brain and spinal fluid studies to be the most accurate Alzheimer's marker available today. The urinary test shows huge potential to become a real ground-breaker in the global effort to overcome this disease. Therapy begins with accurate and objective clinical and laboratory diagnosis. The full results from our trials will be reported later at medical conferences," said Dr. Michael Munzar, Nymox's Medical Director.
The new test has been developed from Nymox's AD7C(TM) NTP based technologies and is entirely painless and non-invasive for the patient. The underlying basic NTP technology is derived from an ongoing licensing collaboration between Nymox Corporation and the Massachusetts General Hospital.
Nymox Corporation is based in Rockville, MD and in Montreal, Canada. In addition to its Alzheimer testing technologies, the company has six treatment entities targeted for Phase One testing in the next 12 to 18 months, and two new diagnostics in development. Nymox currently has begun to launch its AD7C(TM) cerebrospinal fluid Reference Laboratory test in the U.S. and in Europe for use in Alzheimer's disease. The Ad7C(TM) test was shown in multicenter clinical trials in 1996 to be as accurate as an autopsy in Alzheimer's disease. The full results from the AD7C(TM) spinal fluid studies will be made available through appropriate publication in a medical journal.
Nymox is listed on the Montreal Exchange under the symbol NMX.
CONTACT: Nymox Pharmaceutical Corporation
Dr. Michael Munzar, 800/93NYMOX
info@nymox.com
http://www.nymox.com
In addition, make sure to read these articles:
- Elan to Sponsor the 9th International Conference on Alzheimer's Disease.
- Power3's Biomarkers 'Show Great Promise' for Alzheimer's Diagnostics...
- Nymox Develops New Alzheimer Drug Candidate.
- Nymox Corp. Makes Announcement.
- Nymox to Begin Trading on NASDAQ on November 25,1997.
- Nymox CEO Wins Court Judgment Against Ex-EmployeeHossein Ghanbari for Breach of Contract...
- Nymox Corporation Announces Year-endResults.
- Nymox Announces Development of New Urinary Test forAlzheimer's Disease.
- Advisory Board of Medical Experts Support Use of NymoxAlzheimer Test.
- Nymox Makes Announcement.
- Nymox Launches U.S. Subsidiary.
- Nymox's New E. Coli Treatment Shows PromisingResults.
- Nymox Develops Powerful New Antibacterial for ChronicUrinary Infections.
- Nymox Develops Powerful New Antibacterial for ChronicUrinary Infections.
- Nymox and Healthchoice Sign Letter of Agreement forTest Reimbursement.
Email
Digg It
del.icio.us
Related Resources
Business Resources
Sponsored Links
Site Map | Contact Us | FAQs | About Us | Media Kit | Reprints | RSS Directory | Sign Up for Free Newsletters | Disclosure Policy
Copyright © 1999 - 2008 AllBusiness.com, Inc. All rights reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Copyright and Intellectual Property Policy, Terms of Use Agreement and Privacy Policy.
© COPYRIGHT 1997 Business Wire
You may not repost, republish, reproduce, package and/or redistribute the content of this page,
in whole or in part, without the written permission of the copyright holder.
Online Business Database | Online Business Information | Email Marketing Lists | Sales and Marketing Solutions | Business Mailing Lists
AllBusiness.com, its parent company D&B, and its affiliates.
